Search hospitals

>

California

>

Orange

Children's Hospital of Orange County

Claim this profile

Orange, California 92868

Global Leader in Cancer

Global Leader in Solid Tumors

Conducts research for Brain Tumor

Conducts research for Acute Lymphoblastic Leukemia

Conducts research for Leukemia

527 reported clinical trials

22 medical researchers

Photo of Children's Hospital of Orange County in OrangePhoto of Children's Hospital of Orange County in OrangePhoto of Children's Hospital of Orange County in Orange

Summary

Children's Hospital of Orange County is a medical facility located in Orange, California. This center is recognized for care of Cancer, Solid Tumors, Brain Tumor, Acute Lymphoblastic Leukemia, Leukemia and other specialties. Children's Hospital of Orange County is involved with conducting 527 clinical trials across 816 conditions. There are 22 research doctors associated with this hospital, such as Elyssa M. Rubin, Mariko Sato, Josephine H. Haduong, and Raymond Wang, MD.

Area of expertise

1

Cancer

Global Leader

Children's Hospital of Orange County has run 75 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage I
Stage II
2

Solid Tumors

Global Leader

Children's Hospital of Orange County has run 72 trials for Solid Tumors. Some of their research focus areas include:

Stage IV
ROS1 positive
NTRK positive

Top PIs

Clinical Trials running at Children's Hospital of Orange County

Cancer

Brain Tumor

Leukemia

Testicular cancer

Solid Tumors

Brain Cancer

Wilms Tumor

Neuroblastoma

Burkitt Lymphoma

Ovarian Cancer

Image of trial facility.

Chemotherapy

for Cancer

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.

Recruiting

2 awards

Phase 3

26 criteria

Image of trial facility.

Triptorelin

for Cancer

This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part of standard chemotherapy, but may cause damage to the ovaries. If the ovaries are not working well or completely shut down, then it will be difficult or impossible to get pregnant in the future. Triptorelin works by blocking certain hormones and causing the ovaries to slow down or pause normal activity. The triptorelin used in this study stays active in the body for 24 weeks or about 6 months after a dose is given. After triptorelin is cleared from the body, the ovaries resume normal activities. Adding triptorelin before the start of chemotherapy treatment may reduce the chances of damage to the ovaries.

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

Tagraxofusp

for Blood Cancers

Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patients with relapsed/refractory hematologic malignancies. The mechanism by which tagraxofusp kills cells is distinct from that of conventional chemotherapy. Tagraxofusp directly targets CD123 that is present on tumor cells, but is expressed at lower or levels or absent on normal hematopoietic stem cells. Tagraxofusp also utilizes a payload that is not cell cycle dependent, making it effective against both highly proliferative tumor cells and also quiescent tumor cells. The rationale for clinical development of tagraxofusp for pediatric patients with hematologic malignancies is based on the ubiquitous and high expression of CD123 on many of these diseases, as well as the highly potent preclinical activity and robust clinical responsiveness in adults observed to date. This trial includes two parts: a monotherapy phase and a combination chemotherapy phase. This design will provide further monotherapy safety data and confirm the FDA approved pediatric dose, as well as provide safety data when combined with chemotherapy. The goal of this study is to improve survival rates in children and young adults with relapsed hematological malignancies, determine the recommended phase 2 dose (RP2D) of tagraxofusp given alone and in combination with chemotherapy, as well as to describe the toxicities, pharmacokinetics, and pharmacodynamic properties of tagraxofusp in pediatric patients. About 54 children and young adults will participate in this study. Patients with Down syndrome will be included in part 1 of the study.

Recruiting

1 award

Phase 1

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Children's Hospital of Orange County?

Where is Children's Hospital of Orange County located?

Who should I call to ask about financial aid or insurance network?

What insurance does Children's Hospital of Orange County accept?

What awards or recognition has Children's Hospital of Orange County received?